X4 Pharmaceuticals (XFOR) Total Liabilities (2017 - 2025)

X4 Pharmaceuticals' Total Liabilities history runs 9 years deep, the most recent figure standing at $104.2 million for Q4 2025.

• Quarterly Total Liabilities fell 16.19% year-over-year to $104.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $104.2 million (down 16.19% YoY) and the FY2025 annual result came in at $104.2 million, down 16.19% from the prior year.
• Total Liabilities was $104.2 million for Q4 2025 at X4 Pharmaceuticals, up from $101.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $124.3 million in Q4 2024 and bottomed at $49.9 million in Q1 2022.
• A 5-year average of $85.5 million and a median of $98.7 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities surged 107.8% — and 2025, when it decreased 16.19%.
• X4 Pharmaceuticals' Total Liabilities stood at $52.8 million in 2021, then soared by 54.53% to $81.5 million in 2022, then climbed by 17.94% to $96.2 million in 2023, then climbed by 29.26% to $124.3 million in 2024, then slipped by 16.19% to $104.2 million in 2025.
• Business Quant data shows XFOR's Total Liabilities at $104.2 million in Q4 2025, $101.9 million in Q3 2025, and $101.2 million in Q2 2025.